In two cohorts we found that VR tau‐PET‐negative AD patients were older and had less cognitive impairment, slower cognitive decline, and less hippocampal atrophy compared to tau‐PET‐positive AD patients. This evidence concerns the gene MAPT and Mental deterioration.